Analysis of Clinical Characteristics and prognosis of EML4-ALK Positive and Surgically Resected Lung

来源 :第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 | 被引量 : 0次 | 上传用户:maxine1234
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Objective: Along with the research progress of lung cancer-related driver genes, echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinas (EML4-ALK) positive non-small cell lung cancer (NSCLC), which is a distinctive molecular subtype, has been concerned.
其他文献
目的:晚期乳腺癌特别是三阴患者,往往化疗不敏感,常常广泛侵犯皮肤或周围组织,部分有皮肤的溃烂流血,生活质量很差。为提高患者生活质量,减少肿瘤负荷,为术后的放疗化疗提供条件,行局部的扩大切除是很有必要的。但是该类手术常常导致胸壁广泛的缺损,修复非常困难。下腹部皮瓣为修复此类缺损的优良供区,但单蒂腹壁下动脉穿支(DIEP)或腹直肌(TRAM)的3区和4区常血供不足,而我们在修复如此巨大创面时又不能去掉
会议
Objective: Defining the status of single lung lesion and making treatment strategy was intricate, and had been well studied for decades.However, seldom studies had focused on this issue in patients wi
Objective: Rapid growth of tumor cells needs to consume large amounts of oxygen and glucose, due to lack of blood supply within the tumor, cells live in an environment that lack of oxygen and nutrient
Background: The combination of the highly selective c-Met inhibitor tepotinib (MSC2156119J) + gefitinib was shown to be well tolerated and have antitumor activity possibly associated with c-Met-positi
会议
目的:局部进展期胃癌(Locally advancedgastric cancer,LAGC)D2根治术后是否需要辅助放化疗(Chemoradiotherapy,CRT)目前仍存在争议.INT0116试验证明术后辅助放化疗优于单纯手术,然而ARTIST研究结果表明与术后辅助化疗(Chemotherapy,CT)相比,辅助放化疗并未带来生存获益.
Objective: Recent studies indicate that autophagy is adouble-edged sword in tumor genesis and plays an important role in theresistance of cancer cells to chemotherapy.We hypothesize that autophagy pro
Objective: Small cell lung cancer (SCLC) is a refractory subtype of lung cancer characterized by limited drug responses, aggressive metastasis and relapse at relatively earlystage when compared to non
目的:甲苯磺酸多纳非尼是一种新开发的口服多激酶抑制剂类多靶点小分子抗肿瘤药物,可抑制VEGFR、PDGFR、Raf等多种受体激酶和其下游的Raf/MEK/ERK信号传导通路,达到抑制肿瘤细胞增殖和肿瘤血管新生的多重抗肿瘤作用。
Objective: To observe the efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib for advanced non-small cell lung cancer patients with secondary drug resistanceto standard
目的: Malignant pleuraleffusion (MPE) is mainly caused by metastatic pleuralcancer and defines malignant tumors with apoor prognosis.To achieve sufficient control of MPE and to minimize invasive interve